Brachytherapy News
-
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
The growing body of information regarding Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’s annual conference in Denver, Colorado. During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory ...
By Isoray Inc.
-
Promaxo Announces Sale of In-Office MRI to Arizona State Urological Institute
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona State Urological Institute (“ASUI”). Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide ...
-
Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131
Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 brachytherapy, commercially known as Cesium Blu. The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results ...
By Isoray Inc.
-
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131
The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131 has been included in ABS’s highly respected consensus guidelines. Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes ...
By Isoray Inc.
-
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection. The prospective series was conducted at the University Hospitals Cleveland Medical ...
By Isoray Inc.
-
Elekta Studio Launch
We are celebrating the launch of Elekta Studio this week! “On behalf of all at medPhoton, we are delighted about this cooperation with Elekta.” says Heinz Deutschmann, CEO. “A large number of our employees have a longstanding background in Radiation Oncology, where for many years we have developed technologies for adaptive image guided solutions for treatments with linear ...
-
C4 Imaging Announces FDA 510(k) Clearance of its Positive-Signal High Dose Rate (HDR) Brachytherapy MRI Treatment Planning Marker
C4 Imaging LLC announces U.S. Food and Drug Administration 510(k) clearance of its second major brachytherapy product, the HDR MRI Marker. This novel, Positive-Signal MRI Marker will be used prior to high dose rate (HDR) brachytherapy to accurately locate the position of the applicators that guide the placement of radioactive sources for the treatment of multiple cancers. High dose rate (HDR) ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you